Scholar Rock Holding (SRRK) Accumulated Depreciation & Amortization (2017 - 2025)
Scholar Rock Holding's quarterly Accumulated Depreciation & Amortization came in at $14.9 million in Q4 2025, up 12.54% year-on-year from $13.2 million in Q4 2024, and up 12.54% quarter-over-quarter from $13.2 million in Q4 2024.
Scholar Rock Holding has reported Accumulated Depreciation & Amortization for 9 years, with the latest figure at $14.9 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 12.54% year-over-year to $14.9 million; the trailing twelve-month figure through Dec 2025 stood at $14.9 million (up 12.54% YoY), and the FY2025 full-year result was $14.9 million, up 12.54% from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 stood at $14.9 million, up from $13.2 million in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $14.9 million in Q4 2025, with the low at $7.3 million in Q4 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $11.4 million, with a median of $11.3 million recorded in 2023.
- Year-over-year, Accumulated Depreciation & Amortization surged 50.05% in 2021 and climbed 10.7% in 2023.
- Tracing SRRK's Accumulated Depreciation & Amortization over 5 years: stood at $7.3 million in 2021, then soared by 40.32% to $10.2 million in 2022, then rose by 10.7% to $11.3 million in 2023, then grew by 16.7% to $13.2 million in 2024, then climbed by 12.54% to $14.9 million in 2025.
- The last three Accumulated Depreciation & Amortization figures came in at $14.9 million (Q4 2025), $13.2 million (Q4 2024), and $11.3 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.88 Mn |
| Dec 31, 2025 | 14.88 Mn |
| Dec 31, 2024 | 13.22 Mn |
| Dec 31, 2024 | 13.22 Mn |
| Dec 31, 2023 | 11.33 Mn |
| Dec 31, 2023 | 11.33 Mn |
| Dec 31, 2022 | 10.23 Mn |
| Dec 31, 2022 | 10.23 Mn |
| Dec 31, 2021 | 7.29 Mn |
| Dec 31, 2021 | 7.29 Mn |
| Dec 31, 2020 | 4.86 Mn |
| Dec 31, 2020 | 4.86 Mn |
| Dec 31, 2019 | 3.56 Mn |
| Dec 31, 2019 | 3.56 Mn |
| Dec 31, 2018 | 2.36 Mn |
| Dec 31, 2018 | 2.36 Mn |
| Sep 30, 2018 | 2.12 Mn |
| Sep 30, 2018 | 2.12 Mn |
| Jun 30, 2018 | 1.91 Mn |
| Jun 30, 2018 | 1.91 Mn |
| Dec 31, 2017 | 1.55 Mn |
| Dec 31, 2017 | 1.55 Mn |